We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
INLURIYO Eli Lilly Australia Pty Ltd
Product name
INLURIYO
Sponsor
Accepted date
Apr-2025
Active ingredients
imlunestrant tosilate
Proposed indication
INLURIYO (imlunestrant tosilate) is for the treatment of adults with a specific type of breast cancer that has spread to other parts of the body and that was previously treated with hormone therapy.
Application type
A (new medicine)
Publication date
Apr-2025